Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
Last trade$1.81
Day change+$0.02 (+1.12%)
Day range$1.74 – $1.85
Volume1,457,997
Market cap$107M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$107.33M
Price / earnings
11.39×
Price / book
-7.62×
Price / sales
0.96×
EV / sales
0.24×
EV / EBITDA
2.24×
Profitability
Earnings per share
$0.16
Return on assets
4.93%
Return on equity
-66.88%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0×
Current ratio
4.24×
Quick ratio
4.24×
Cash ratio
2.15×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$83.68M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for FHTX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$83.54M
$16.07M
$3.27M
$9.25M
$8.15M
$7.56M
$5.95M
$2.86M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$83.54M
$16.07M
$3.27M
$9.25M
$8.15M
$7.56M
$5.95M
$2.86M
Selling, general and administrative
$5.8M
$6.35M
$6.58M
$6.8M
$6.65M
$6.86M
$7.24M
$6.35M
Research and development
$18.84M
$18.52M
$18.26M
$22.05M
$20M
$21.79M
$21.63M
$20.51M
Total operating expenses
$26.9M
$24.88M
$24.84M
$33.13M
$26.65M
$28.65M
$28.87M
$26.86M
Operating income
$56.64M
-$8.81M
-$21.57M
-$23.88M
-$18.5M
-$21.1M
-$22.91M
-$24.01M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$58.15M
-$7.19M
-$19.88M
-$21.66M
-$15.85M
-$17.94M
-$18.83M
-$19.5M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
$58.15M
-$7.19M
-$19.88M
-$21.66M
-$15.85M
-$17.94M
-$18.83M
-$19.5M
Net income attributable to common shareholders
$58.15M
-$7.19M
-$19.88M
-$21.66M
-$15.85M
-$17.94M
-$18.83M
-$19.5M
EBITDA
$59.13M
-$8.58M
-$21.34M
-$17.16M
-$17.65M
-$20.25M
-$22.09M
-$23.24M
Basic earnings per share
$0.81
-$0.10
-$0.29
-$0.34
-$0.25
-$0.28
-$0.30
-$0.31
Diluted earnings per share
$0.80
-$0.10
-$0.29
-$0.34
-$0.25
-$0.28
-$0.30
-$0.31
Recent news
Company coverage with links to the original publishers.
Foghorn Therapeutics reported Q3 2026 earnings of $0.8 per share, significantly beating the consensus estimate of a loss of $0.23 per share, with a 447.83% earnings surprise. Revenues reached $83.54 million, vastly exceeding the consensus estimate by 974.37%. However, the stock has underperformed the market, declining 65.4% year-to-date compared to the S&P 500's 7.8% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Foghorn Therapeutics (FHTX) is expected to beat Q3 2026 earnings estimates with a positive Earnings ESP of +7.08% and Zacks Rank #3, though revenues are projected to decline 4.5% year-over-year. The company has a history of beating estimates, with a +56.52% surprise in the last quarter. Amgen (AMGN), a comparable industry player, shows mixed signals with a negative Earnings ESP of -1.82% despite consistent historical beats.
Step Pharma appoints Neil J. Gallagher, MD, PhD as Non-Executive Director to strengthen its board as it advances dencatistat, a first-in-class CTPS1 inhibitor, across three clinical programmes for essential thrombocythaemia, lymphoma, and solid tumours. Gallagher brings over 25 years of clinical development experience from senior roles at major pharmaceutical companies including Amgen, AstraZeneca, Novartis, and AbbVie.
Foghorn Therapeutics announced it will present multiple oral and poster presentations at the 2026 AACR Annual Meeting in San Diego. The company will showcase new preclinical data for FHD-909 (LY4050784), a selective SMARCA2 inhibitor developed with Eli Lilly for SMARCA4-mutant cancers, including potential combination opportunities with anti-PD-1 antibodies. Additional presentations will highlight preclinical progress on selective CBP, EP300, and ARID1B degrader programs targeting various cancer types.
The precision oncology market is projected to grow from $110 billion to $225.65 billion by 2032, driven by Big Pharma's race to acquire registration-ready assets ahead of a $170 billion patent cliff through 2030. Several biotech companies are advancing promising clinical programs: Oncolytics Biotech strengthened its leadership team for pelareorep development in gastrointestinal cancers; Nurix is executing pivotal studies for its BTK degrader bexobrutideg in chronic lymphocytic leukemia; Erasca reported early clinical data for its pan-RAS molecular glue ERAS-0015; Foghorn raised $50 million for its SMARCA4-targeting program; and ORIC presented strong Phase 1b data for rinzimetostat in prostate cancer.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.